T rauma is a the leading cause of death and disability in adults worldwide. 1 The vast majority of reversible death is due to hemorrhage, which tends to occur within 6 to 24 hours after injury. [2] [3] [4] [5] [6] Transfusion of blood is critical in managing hemorrhage and 1% to 3% of civilian trauma admissions 7, 8 may require massive transfusion (MT), commonly defined as 10 units of blood within 24 hours. 9 Injured patients frequently manifest coagulopathy on admission and this has been associated with increased mortality. 10 -12 Management of trauma-related coagulopathy in part includes transfusion of coagulation factors and platelets, 13 though optimal transfusion strategies remain poorly understood. Appropriate plasma to red blood cell (RBC) ratios has been identified as a critical component in managing massively transfused patients, 14 -18 though fewer data exist regarding the appropriate ratios for platelets. 19, 20 At the US Army's Combat Support Hospital (CSH) in Baghdad, Iraq, stored RBCs, fresh frozen plasma (FFP), and cryoprecipitate (cryo) were routinely available to treat casualties requiring massive resuscitation. In November 2004, the CSH obtained apheresis machines allowing for collection and use of apheresis platelets (aPLT) in the management of casualties. The availability of such aPLT offered an opportunity to examine the outcomes of massively transfused combat casualties related to different platelet to RBC ratios. hours were identified. Patients who were treated initially at forward surgical units/local hospitals before transfer to Ibn Sina Hospital, or who received their MT as a complication during their hospital course/not on the day of their admission (e.g., after the first 24 hours as with an excision/grafting of burns, or for gastrointestinal bleeding) were excluded from analysis. Because of difficulty comparing the equivalence of platelets from fresh whole blood to those receiving aPLT, patients receiving fresh whole blood were also excluded from the analysis.
Three groups of patients were defined and evaluated: (1) patient receiving a low ratio of platelets (Ͻ1:16 apheresis platelets per stored red cell unit, aPLT:RBC), (2) patients receiving a medium ratio of platelets (1:16 to Ͻ1:8 aPLT: RBC), and (3) patients receiving a high ratio of platelets (Ն1:8 aPLT:RBC). We chose Ն1:8 aPLT:RBC as the high platelet ratio group based on previously published data with survivors receiving 1:7.7 apheresis units:RBC as compared with nonsurvivors (1:11.9). 20 The primary endpoint was survival at 24 hours and at 30 days. Stored blood products (RBCs, FFP, and cryo) were obtained almost exclusively from the United States through the Armed Services Blood Program. aPLT were collected using the Hemonectics' Component Collection System (Braintree, MA) from healthy donors at the hospital, and a MT protocol was in place for the hospital to guide resuscitation.
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Data Sources
The data presented here were obtained under a human use protocol that received Institutional Review Board approval through the Department of Clinical Investigation at Brooke Army Medical Center in San Antonio, TX. Theater transfusion records maintained within the Department of Defense Armed Services Blood Program Office database in Falls Church, VA were used to identify massively transfused patients and individual blood products. The Joint Theater Trauma Registry (JTTR) maintained at the US Army Institute for Surgical Research at Ft. Sam Houston in San Antonio, TX was used to determine baseline patient demographics and determine outcomes for evacuated patients. For United States military casualties discharged from the hospital before 30 days, out-patient visits were noted in the joint patient tracking application, which provides information on location and status of soldiers near real time through a web-based application. Mortality and dates of death were cross referenced with Social Security Death Index records and listing of casualties provided on the online website Iraq Coalition Casualty Count (www.icasualties.org).
Individual patient chart review was performed on inpatient records to verify vitals, laboratory reports, blood product transfusions, and outcomes before evacuation or transfer from the CSH. Such charts were viewed directly or by using the Patient Administration Systems and Biostatistics Activity system, which receives all in-patient records from deployed medical units. Blood product usage and timing of blood product administration were identified from the chart, and were compared against the JTTR and the ASBPO Blood Bank transfusion record. Discrepancies were reconciled by comparing the times recorded on blood transfusion slips, anesthesia records, intensive care unit records, operative reports, and discharge summaries. Most discrepancies occurred in the context of missing/incomplete blood transfusion slips, double counting of carbon copies of blood transfusion slips, misdocumentation of blood products (e.g., RBCs recorded as FFP, or FFP recorded as RBCs), inaccurate documentation on anesthesia records, or failure to attribute emergency release blood products to the specific recipient by the blood bank. The comparison of multiple databases with correlation to the patient record represents the most accurate and complete dataset possible.
Data Collection
After identification, patient charts were evaluated for age, gender, admission vital signs, Glasgow Coma Scale, admission laboratory tests, mechanism of injury, documented injuries, 24 hour blood product administration (RBC, FFP, cryo, and aPLT), and recombinant factor VIIa (rFVIIa) administration and dosage. Plasma ratios (%) were calculated as (FFP/RBC) ϫ 100. Apheresis platelet ratios (%) were calculated as (aPLT/RBC) ϫ 100. Revised Trauma Scores (RTS) were calculated using admission vitals signs. 22 Abbreviated injury scales and Injury Severity Scores (ISS) were centrally scored and calculated by trained research nurses and staff using ISS-98 after patient discharge. 23 Trauma and Injury Severity Scores were calculated using age, mechanism of injury, RTS, and ISS-98. 24 The primary outcomes evaluated were survival at 24 hours and at 30 days. US soldiers were tracked for survival as they reached higher echelons of care. Iraqi casualties who were discharged before 30 days were generally lost to follow-up unless they were seen as out-patients in follow-up or were readmitted to the combat hospital. Secondary outcomes, including causes of death from central nervous system injury, exsanguination, airway failure, multisystem organ failure (in patients surviving Ͼ24 hours), and arterial or venous embolism were evaluated using the JTTR and available in-patient records from Ibn Sina Hospital, US military hospitals in Germany, and US military hospitals in the continental US.
Statistical Analysis
Baseline characteristics, blood product transfusion, rFVIIa usage, and survival at 24 hours and at 30 days were compared between patient groups. Data were evaluated for normality using Kolmogorov-Smirnov, Shapiro-Wilk, and normality plots. Analysis of variance was used to compare parametric data between groups. Kruskal-Wallis and pairwise MannWhitney U was used to compare nonparametric data between groups. Pearson 2 was used to compare dichotomous variables between groups. Kaplan-meier log-rank was used to compare groups for survival at 24 hours and at 30 days. Continuous data are presented as median (range) for nonparametric data or mean (SD) for parametric data, as indicated. Statistical significance was set at a p £0.05 for all group comparisons.
To adjust for potential confounders, we used multivariable logistic-regression analysis of 24-hour survival and Coxproportional hazards model of 30-day survival for baseline variables, excluding variables subsumed within other variables (e.g., systolic blood pressure, respiratory rate, and Glasgow Coma Scale are used to calculate RTS). Variables with p Ͻ0.1 on univariate analysis were included in the multivariate analyses. To control for confounding, a propensity score was calculated from a logistic regression as the probability of receiving a platelets given variables that would influence the decision to administer platelets (abbreviated injury severity by body region, admission temperature, admission platelet count, admission systolic blood pressure, admission international normalized ratio (INR), admission base deficit, RBC units given over 24 hours, FFP units given over 24 hours, the plasma ratio in first 24 hours, and rFVIIa dosage over 24 hours). This logistic regression model for propensity to administer platelets had a receiver operating characteristic area under the curve ϭ 0.91. This propensity score was then forced into the logistic and Cox-proportional hazards models for survival to adjust for confounding. Regressions were also performed without the propensity score and relationships between variables were unaffected (data not shown). Statistical analysis was performed with SPSS 15.0 (Chicago, IL).
RESULTS
Over the 36-month period between January 2004 and December 2006, the CSH received 8,618 patients with traumatic injuries, of which 2,024 (23%) were transfused with 694 (8.1%) identified as having received 10 or more units of RBCs within 24 hours at the hospital (Fig. 1) . On review of in-patient records, 230 patients were excluded from the analysis: 18 patients had a MT during their hospital course and not within 24 hours of admission (e.g., during excision and grafting of burns, or gastrointestinal bleeding), 84 patients were treated at forward surgical teams or local hospitals before transfer to the combat hospital, and 128 patients received fresh whole blood. Of the remaining 462 patients, 214 patients received Ͻ1:16 aPLT:RBC (low platelet ratio group), 154 patients received between 1:16 to Ͻ1:8 aPLT:RBC (medium platelet ratio group), and 96 patients received Ն1:8 aPLT:RBC (high platelet ratio group).
Characteristics of the Patients
The three groups were similar (Table 1 ) on the basis of admission demographics, ISS, RTS, vital signs, and admission laboratory studies. The patients were primarily young (median age, 27-28), male (Ͼ95%), with median ISS 20 to 21, and the vast majority had a penetrating mechanism of injury (Ͼ90%). There were no differences between groups for admission vitals, or admission laboratories with groups tending to be acidotic (median pH, 7.24 -7.25, median base deficit of 7-8 mEq/L), slightly anemic (median hemoglobin, 11.1-11.4 g/dL), and with median INR of 1.4 to 1.5. There 
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were multiple differences between groups regarding resuscitation management (Table 2 ), but in general the low platelet ratio group received the fewest stored RBC, FFP, aPLT, and cryo units as well as the lowest FFP:RBC ratio as compared with the medium and high platelet ratio groups ( p Ͻ 0.001 for all pairwise comparisons). The high platelet ratio group received more RBC, FFP, and aPLT as compared with the medium platelet ratio group ( p ϭ 0.02, 0.01, and Ͻ0.001 for pairwise comparisons respectively), though these two groups received similar plasma ratios and cryo units. All groups differed from one another with respect to rFVIIa administration with 78%, 62%, and 46% of patients receiving rFVIIa in the high, medium, and low platelet ratio groups, respectively ( p Ͻ 0.01 for all pairwise comparisons). When administered, the dose of rFVIIa was highest in the high platelet ratio group (median, 9.6 mg) as compared with both the low and medium platelet ratio groups (both with median of 7.2 mg, and p Ͻ 0.001 and p ϭ 0.02 for pairwise comparisons versus the high platelet ratio group, respectively).
Outcomes
The primary outcome of survival (Table 3) at 24 hours was 64%, 87%, and 95% in the low, medium, and high platelet ratio groups, respectively ( 2 , p Ͻ 0.001 for low versus medium and high platelet ratio group comparisons, 2 , p ϭ 0.04 for medium versus high platelet ratio group com- parisons), and most deaths in the first 24 hours occurred within 6 hours of admission (Fig. 2) . Differences in 30-day survival between the low platelet ratio (42.7%) group as compared with the medium (60%) and high platelet ratio (75%) groups remained highly significant ( p Ͻ 0.001 logrank for both comparison). Because of the number of patients lost to follow-up, the difference in 30-day survival between the medium and high platelet ratio groups could not be established (Log-rank, p ϭ 0.13). Regarding secondary outcomes, the median time to death was shorter in the low platelet ratio group (2.3 hours) as compared with the medium (7.6 hours) and high (80.2 hours) platelet ratio groups ( p Ͻ 0.001 both comparisons). Exsanguination represented 28.6%, 8.6%, and 2.1% of the causes of death in the low, medium, and high platelet ratio groups, respectively, ( p Ͻ 0.001 for low versus medium and high platelet ratio group comparisons, p ϭ 0.04 for medium versus high platelet ratio group comparisons). Other causes of death to include central nervous system, multiorgan failure syndrome, airway failure, and embolism were similar between groups.
Because of differences in the resuscitation management, a univariate regression analysis of variables was performed examining mortality at 24 hours and 30 days (Table 4) . Variables influencing survival with p Ͻ 0.1 on univariate analysis were then used for multivariate analysis at 24 hours and 30 days (Table 5) 
DISCUSSION
This article represents the largest comparative analysis examining the impact of platelet ratios in massively transfused combat casualties with penetrating injury published to date. Corroborating what has been noted in the civilian literature, both platelets and plasma seem to be key components in managing massively transfused trauma patients. 18 These data are important as clinically relevant thrombocytopenia has previously been considered a delayed complication of MT based on data published during the era of stored whole blood transfusion, which showed that circulating platelet counts dropped to Ͻ50 ϫ 10 3 /mm 3 only after multiple blood volume replacements. 25 However, assumptions of "clinically relevant thrombocytopenia" do not take into account platelet dysfunction in trauma due to acidosis, hypothermia, or outpatient medications with activity against platelets such as aspirin/nonsteroidal antiinflammatory drugs (NSAIDS) or clopridogrel. 26 -28 The optimal timing of platelet administration has not been clearly defined by these data and given that the majority of deaths occurred by 6 hours, it would be appropriate to examine this time point more closely. Such data in combat casualties are not available at the time of this publication, but are forthcoming.
The optimal ratio of platelets to administer during a MT has also not been precisely defined. We chose Ն1:8 aPLT: RBC as the high platelet ratio group based on previously published data in forty-five massively transfused patients with survivors receiving 1:7.7 apheresis units:RBC as compared with nonsurvivors (1:11.9). 20 For centers using pooled platelets instead of aPLT, assuming that one unit of aPLT is approximately equal to 6 units of pooled platelets, the equivalent ratio would be 0.75:1 or 4:6 pooled platelets:RBC. This pooled-platelet:RBC ratio is supported by data from a study examining fifty-eight massively transfused patients showing that survivors received higher ratios of pooled platelets (0.8:1) as compared with nonsurvivors (0.5:1). 19 Both of these studies were reported out of civilian trauma centers that have a higher proportion of blunt mechanism injuries (e.g., motor vehicle accidents and falls). Our data add to the evidence of an association between platelets and survival in a cohort of combat casualties suffering primarily from penetrating injuries (e.g., high-velocity gun shot wounds and fragmentation injuries).
As this is a retrospective analysis, these data are hypothesis generating as they only show an association between the platelet ratio and survival and cannot be used to make definitive conclusions about the best care for trauma casualties. The exclusion of patients receiving less than 10 units of blood in 24 hours may have inadvertently introduced bias in that patients may have died quickly before being able to receive 10 units, though very few of such patients would have received platelet products. The exclusion of patients undergoing surgery at forward surgical hospitals may also have introduced bias because platelets would have been transfused much longer after injury than in patients arriving de novo to the hospital. This being said, an informal examination of survival in patients treated at forward surgical hospitals showed similar 30-day survival trends between the different ratio groups (43%, 62%, and 73% in the low, medium, and high platelet ratio groups, respectively, p ϭ NS). This was a retrospective study in patients where clinical decisions were made at the bedside and treatment groups were not assigned. Some casualties may have been so severely injured that the surgeon may have made a triage decision that the casualty did not warrant the commitment of resources necessary to consume a relatively limited resource such as aPLT. One might also argue that there is a survival bias inherent for patients who receive more aPLT as this blood product may have been reserved for late in the resuscitation. This is somewhat supported by the fact that the median time to aPLT transfusion was 2.5 hours (interquartile range, 1.4 -4.4 hours), whereas the median time to death of patients in the low platelet ratio group was 2.3 hours (interquartile range, 1.2-3.8 hours). A propensity analysis was performed to account for such decision making, but it remains possible that patients received platelets because they lived as opposed to living because they received platelets. Given the significant differences in resuscitation between groups, one might wonder whether this is a reflection on changing patterns in resuscitation during time. An analysis of this was performed and patients in the low platelet ratio group did come from earlier in the time period than patients in the other two groups, which can be partially explained by the fact that aPLT were unavailable before November 2004 (when apheresis machines were deployed to the hospital). There were no such time period differences between the medium and high platelet ratio groups. An additional limitation is that we did not report on important outcomes secondary such as ventilator days, intensive care unit days, or hospital length of stay. Finally, the findings of this study are limited to patients receiving a MT in the setting of trauma and care should be taken before extrapolating these results to patients undergoing elective surgery or patients expected to receive less than 10 units of blood.
In conclusion, increased platelet:RBC and plasma:RBC ratios are associated with increased survival in the setting of MT. Randomized trials are needed to examine the optimal timing of platelet administration (such as proactively administering platelets before the 8th unit of blood as opposed to reactively after receiving the 8th unit of blood) and the optimal ratios for transfusing platelets. Until such data are available, transfused platelets should be considered an integral component in patients requiring MT and incorporated into transfusion protocols at medical facilities managing trauma.
